Alan H. Auerbach
Neratinib (Nerlynx) led to a statistically significant improvement in centrally confirmed progression-free survival (PFS) compared with lapatinib (Tykerb) and capecitabine in patients with HER2-positive metastatic breast cancer who have failed 2 or more prior lines of HER2-directed therapy, according to topline findings of the phase III NALA trial (NCT01808573).1
Results of the analysis demonstrated that, in both the EXTENT and CONTROL studies, FACT-B total score decreases were seen in early months followed by recovery towards baseline levels.
- Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer. Puma BioTechnology. Published December 17, 2018. https://on.mktw.net/2S8jMcB?rel=0" . Accessed December 17, 2018.
- Singh H, Walker AJ, Amiri-Kordestani L, et al. U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer. Clin Cancer Res. 2018;24(15):3486-3491. doi: 10.1158/1078-0432.CCR-17-3628.
- Delalogue S, Hurvitz S, Chan N, et al. The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in HER2+ early-stage breast cancer: Analyses from the ExteNET and CONTROL trials. In: Proceedings from the 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. Abstract P2-13-03.
... to read the full story